Author: ["Sandip Ray","Markus Britschgi","Charles Herbert","Yoshiko Takeda-Uchimura","Adam Boxer","Kaj Blennow","Leah F Friedman","Douglas R Galasko","Marek Jutel","Anna Karydas","Jeffrey A Kaye","Jerzy Leszek","Bruce L Miller","Lennart Minthon","Joseph F Quinn","Gil D Rabinovici","William H Robinson","Marwan N Sabbagh","Yuen T So","D Larry Sparks","Massimo Tabaton","Jared Tinklenberg","Jerome A Yesavage","Robert Tibshirani","Tony Wyss-Coray"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
A molecular test for Alzheimer's disease could lead to better treatment and therapies. We found 18 signaling proteins in blood plasma that can be used to classify blinded samples from Alzheimer's and control subjects with close to 90% accuracy and to identify patients who had mild cognitive impairment that progressed to Alzheimer's disease 2–6 years later. Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease.Cite this article
Ray, S., Britschgi, M., Herbert, C. et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359–1362 (2007). https://doi.org/10.1038/nm1653 